biote Corp. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 52/100
What the filing says
Biote reported Q3 2026 revenue of $43.3M (down 9.6% from $48.0M in Q3 2025), with procedure revenue declining 15.1% to $28.9M offset partially by dietary supplements growth of 7.3% to $12.0M. Net income fell to $0.6M ($0.01 diluted EPS) from $9.2M ($0.22 EPS) year-over-year, and Adjusted EBITDA declined to $5.1M from $12.9M, due to residual impacts from a January 2026 voluntary product recall. The company maintained full-year 2026 guidance of revenue above $175M and Adjusted EBITDA above $25M despite slower-than-anticipated return to growth.
Why this rating
Revenue decline of ~$5M (5% of $97.9M market cap) and EBITDA halving signal material operational deterioration. Recall aftermath and slowing procedure volumes are real concerns, though guidance maintenance and dietary supplement growth provide some offset. Moderate but not yet trajectory-altering.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.